



Life Sciences Luncheon & Forum

Emerging Therapies: Reshaping How We Treat Disease

January 31, 2019

11:30 a.m. – 1:30 p.m.

NC Biotechnology Center

11:30 a.m. Registration / Check-in

11:35 a.m. Welcome - **Sam Taylor**, President, NC BIO

- **Faye Woolf**, President and Chief Executive Officer, Aperio Clinical Outcomes
- **Tom Fagley**, Partner, Hughes Pittman & Gupton, LLP
- **Chris Capel**, Partner, Smith Anderson

11:45 a.m. Lunch

12:15 p.m. Panel Session: Reshaping How We Treat Disease

*Moderated by **Cartier Esham, Ph.D.**, Executive Vice President, Emerging Companies, BIO*

- **Michael Dombeck**, Senior Vice President of Business Development, Precision Biosciences
- **Tom Jede**, Site Head and Senior Director, Vector Manufacturing, bluebird bio
- **Susan Nichols**, Chief Executive Officer, Falcon Therapeutics
- **Al Pritchard**, Chief Executive Officer, Kaio Therapy

1:25 p.m. Closing - **Sam Taylor**

Thank you to our event sponsors. Speaker bios on reverse side.



In an industry flooded with data, Aperio Clinical Outcomes remains dedicated to transparent interactions with clients and steadfastly focused on the most important part of the process: people. Aperio provides full, customizable clinical research services across multiple therapeutic areas, as well as consulting services in Quality Assurance, Strategic Resourcing and practical application of the latest Clinical Trial Technology. Learn more at www.aperioclinical.com.



BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Visit www.bio.org.



Global expertise with local firm attention. HPG is here to take you to the next level. The key to your business success is a partner who provides proactive, practical business advice to meet your current and future needs. For nearly three decades, HPG has focused on understanding your business first, then providing customized accounting, tax and advisory services to help you grow locally, nationally and internationally. Learn more at www.hpg.com.



Smith Anderson has grown to become the largest business and litigation law firm headquartered in the world-renowned Research Triangle region and one of the largest in North Carolina. We provide a full range of legal services to a dynamic group of regional, national and international companies ranging in size from large public companies to emerging growth businesses. Visit www.smithlaw.com.

Speaker Bios



Michael Dombeck, Senior Vice President of Business Development, Precision Biosciences
Mr. Dombeck has nearly 20 years of industry experience, spanning market research and portfolio planning with Talecris, business development for DarPharma, business development and corporate strategy consulting with Campbell Alliance, and as a co-founder of Cempra Pharmaceuticals. He also served as a director in GlaxoSmithKline's R&D Strategy and Portfolio Management group. He completed both his undergraduate and graduate studies at Duke University, with an MBA and Master of Public Policy, and a B.S. in biology and health policy.



Cartier Esham, Ph.D., Executive Vice President, Emerging Companies, BIO
Dr. Esham manages and directs BIO's policy development, advocacy, research and educational initiatives for BIO's emerging companies. This includes capital formation policy and health policy impacting emerging companies, as well as research and analysis of the biopharmaceutical industry and life-science investment and financing. Prior to joining BIO, Dr. Esham was a Vice President and Director of Research at Dutko Worldwide. She has a Ph.D. in microbiology from the University of Georgia, a master's degree in marine biology from the University of North Carolina at Wilmington and a B.S. from the University of Kentucky.



Tom Jede, Site Head and Senior Director, Vector Manufacturing, bluebird bio
Mr. Jede joined bluebird in April 2018 to design, start-up, and operate the bluebird Research Triangle (bRT) Vector Manufacturing facility in Durham. He has 20 years of GMP manufacturing experience in solid dose, biopharmaceuticals, vaccines, and gene therapy. Mr. Jede has been part of five global companies including Procter & Gamble, GlaxoSmithKline, Novartis, Seqirus, and bluebird bio. He has a degree in chemical engineering from the University of Delaware and graduated from the University of Pennsylvania Wharton Management Program.



Susan Nichols, Chief Executive Officer, Falcon Therapeutics
Ms. Nichols joined Falcon Therapeutics to apply her experience establishing new markets, fundraising, and establishing partnerships to support Falcon's next steps toward regulatory approval and commercialization of its new promising platform oncology cell therapy. She has a proven executive management track record and over 20 years of corporate management and leadership experience in high growth biotech. Ms. Nichols has served in global executive management roles with early stage, emerging, and fortune 500 companies.



Alden Pritchard, Chief Executive Officer, Kaio Therapy
Mr. Pritchard has more than 30 years of leadership and entrepreneurial experience with companies operating in the U.S., China, Russia, France and Poland. In 2012, he purchased control of NanoTherapy Co. Ltd. of Japan and subsequently founded Kaio Therapy, a U.S. medical device company that provides immunomodulatory therapy to patients with solid tumors. He earned a B.A. from the University of North Carolina at Chapel Hill and a MBA from the College of William & Mary's Executive Program.